PharmaJet Poster Presentation at Cancer Immunotherapy Conference Highlights How Needle-free Technology is Enhancing Oncology Solutions

GOLDEN, Colo.--(BUSINESS WIRE)--Nov 5, 2024--

PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced their upcoming poster presentation on November 8, 2024 at the Society of Immunotherapy of Cancer (SITC) conference. The poster (#741), entitled Modulating Immune Responses to Therapeutic Cancer Vaccines through Precision Delivery Technologies, will be presented by Gregg Wilson, PhD, RN, Director of Medical and Scientific Affairs, PharmaJet. The SITC conference will be held at the George R. Brown Convention Center in Houston, Texas, bringing together leading cancer immunotherapy researchers, clinicians, scientists and industry leaders in the oncology field.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105182649/en/

Immunotherapeutic strategies for cancer treatment include nucleic acid platforms with antigen presenting cell (APC)-targeting to boost T cell activation and the addition of neo-antigenic epitopes. Combined with checkpoint inhibitors (CPI), therapeutic vaccines significantly enhance anti-tumor and clinical responses. PharmaJet needle-free delivery can improve DNA vaccine delivery and has been successfully adopted into multiple vaccine development programs while demonstrating robust immunogenicity, with favorable clinical outcomes for novel therapeutic vaccines.

The poster presentation will highlight recent partner study results showing immunogenicity improvement when delivered with the PharmaJet Stratis ® including:

“PharmaJet Needle-free Systems enable DNA cancer vaccine delivery and can be incorporated into both conventional and novel therapeutic strategies to treat various types of cancer,” noted Nathalie Landry, Chief Scientific Officer, PharmaJet. “These study results show that needle-free delivery is safe and well tolerated, induces antigen-specific T cell responses, and leads to favorable clinical outcomes.”

For more information visit the PharmaJet booth #533 from November 8-10, 2024, at the SITC conference, or visit the website at https://pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

1 Ledesma-Feliciano C, et al (2023). Improved DNA Vaccine Delivery with Needle-free Injection Systems. Vaccines. 11(2):280

2 Keline-Kohlbrecher et al (2023). Ai-designed personalized neoantigen vaccine, EVX-02, Induces robust T-cell responses in melanoma patients. Society for Immunotherapy of Cancer (SITC) 2023 poster.

3 Paston, et al (2024). A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma. Cancer immunotherapy as Association (CIMT) 2024 poster.

4 Lindy Durant, Professor and CEO Scancell, Scancell Holdings Chief Executive Officer’s Report, September 24, 2024.

About PharmaJet

The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness and promote a preferred patient and caregiver experience while being safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet to improve the impact of your novel development program, visit https://pharmajet.com or contact PharmaJet here. Follow us on LinkedIn.

ABOUT SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member society of medical professionals dedicated to advancing cancer immunotherapy and biological therapy through its initiatives, educational sessions, and collaborative endeavors. SITC has become the premier forum for innovative discussions in the field and remains a central provider of scientific information for its diverse members serving in academia, industry, and regulatory agencies in the U.S. and abroad.

Modulating Immune Responses to Therapeutic Cancer Vaccines through PharmaJet Precision Delivery Technologies (Graphic: Business Wire)

LILLE, France (AP) — A French court found 18 people guilty Tuesday in a major migrant-smuggling trial that shed light on the lucrative but often deadly clandestine business of transporting people on flimsy boats across the perilous sea from France to the U.K.

The defendants were swept up in a pan-European police operation in 2022 that led to dozens of arrests and the seizure of boats, life jackets, outboard engines, paddles, and cash.

The court in Lille, northern France, sentenced one of the ringleaders, from Iraq, to 15 years in prison and a fine of 200,000 euros ($218,000). Other sentences ranged from two years to 10 years in prison.

“These sentences are obviously very severe,” said Kamel Abbas, a lawyer who represented one of the defendants already imprisoned in France. “That’s a testimony of the scale of the case, and of the intention to severely punish the smugglers.”

Most of the defendants were not in court for the verdicts and sentencing. Some attended the trial remotely from various prisons in northern France, while others are not in custody. Fourteen of the 18 defendants were from Iraq, with the others from Iran, Poland, France and the Netherlands.

The trial comes in what has been a particularly deadly year for attempted crossings of the English Channel, one of the world's busiest shipping lanes.

More than 31,000 migrants have made the perilous Channel crossing so far this year, more than in all of 2023, though fewer than in 2022. At least 56 people have perished in the attempts this year, according to French officials, making 2024 the deadliest since the crossings began surging in 2018.

The route, despite French and British efforts to stop it, remains a major smuggling corridor for people fleeing conflict or poverty. Migrants favor the U.K. for reasons of language, family ties, or perceived easier access to asylum and work.

Europe’s increasingly strict asylum rules, growing xenophobia and hostile treatment of migrants are also pushing many migrants north.

On Monday, British Prime Minister Keir Starmer called for international cooperation against smuggling gangs, likening the issue to a global security threat on par with terrorism.

Starmer told a conference of international police organization Interpol that “people-smuggling should be viewed as a global security threat similar to terrorism.” He said intelligence and law-enforcement agencies should try to “stop smuggling gangs before they act” in the same way they do in counterterrorism operations.

AP journalists John Leicester in Paris and Jill Lawless in London contributed.

Follow all AP stories on global migration at https://apnews.com/hub/migration

FILE - A group of Kurdish migrants from Iran and Iraq who failed in their attempt to reach the United Kingdom by boat walk back to the town of Ambleteuse, northern France, on Sunday, May 19, 2024, after being discovered by the police. (AP Photo/Bernat Armangue, File)